评价狼疮抗凝物、损伤和缓解状态对系统性红斑狼疮妊娠并发症的预测作用:法国GR2研究
法国GR2前瞻性研究纳入238例系统性红斑狼疮(SLE)孕妇(单胎妊娠12周入组,98.3%使用羟氯喹),评估缓解状态、LLDAS和损伤累积对母体复发及不良妊娠结局(APO)的预测作用。孕早期低补体血症是与孕中晚期母体复发相关的唯一因素(P=0.02),而SLICC损伤指数和狼疮抗凝物(LA)与APO显著相关(OR 4.2,95%CI 1.8-9.7)。结论认为受孕时LA和损伤是APO的预测因素。
要点
- 孕早期低补体血症是与孕中晚期母体复发相关的唯一因素(P=0.02)。
- 受孕时SLICC损伤指数和狼疮抗凝物(LA)与不良妊娠结局显著相关。
- 238例孕妇中35例(14.7%)出现母体复发,34例(14.3%)发生至少一种不良妊娠结局。
核心结论
- 狼疮抗凝物(LA)和受孕时损伤是系统性红斑狼疮(SLE)患者不良妊娠结局(APO)的预测因素。
- 孕早期低补体血症与孕中晚期母体复发相关,该队列中多数患者SLE控制良好并使用羟氯喹(HCQ)治疗。
研究设计与样本
- 法国GR2前瞻性研究,纳入238例年龄≥18岁、单胎妊娠12周入组的系统性红斑狼疮(SLE)女性(每例女性一次妊娠)。
- 采用多套标准定义缓解、疾病活动和损伤,检测孕早期母体和疾病特征对母体复发及不良妊娠结局(APO)的预测作用。
- 238例中98.3%使用羟氯喹(HCQ),共230例活产。
主要发现
- 35例(14.7%)患者在孕中晚期至少出现一次复发,34例(14.3%)发生至少一种不良妊娠结局(APO)。
- 孕早期低补体血症是与孕中晚期母体复发相关的唯一因素(P=0.02)。
- 在logistic回归模型中,SLICC损伤指数与APO显著相关(模型1:OR 1.8,95%CI 1.1-2.9;模型2:OR 1.7,95%CI 1.1-2.8)。
- 在logistic回归模型中,狼疮抗凝物(LA)与APO显著相关(模型1:OR 4.2,95%CI 1.8-9.7;模型2:OR 3.7,95%CI 1.6-8.7)。
关键数值与推荐
- 不良妊娠结局(APO)包括:胎儿/新生儿死亡、胎盘功能不全伴早产、小于胎龄儿出生体重。
- 采用多套标准定义缓解、疾病活动和损伤。
- 孕早期低补体血症与孕中晚期母体复发相关(P=0.02)。
- SLICC损伤指数与APO相关(模型1:OR 1.8,95%CI 1.1-2.9;模型2:OR 1.7,95%CI 1.1-2.8)。
- 狼疮抗凝物(LA)与APO相关(模型1:OR 4.2,95%CI 1.8-9.7;模型2:OR 3.7,95%CI 1.6-8.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The specific roles of remission status, lupus low disease activity state (LLDAS), and damage accrual on the prognosis of pregnancies in women with SLE are unknown. We analysed their impact on maternal flares and adverse pregnancy outcomes (APOs). METHODS: We evaluated all women (≥18 years) with SLE enrolled in the prospective GR2 study with an ongoing singleton pregnancy at 12 weeks (one pregnancy/woman). Several sets of criteria were used to define remission, disease activity and damage. APOs included: foetal/neonatal death, placental insufficiency with preterm delivery and small-for-gestational-age birth weight. First trimester maternal and disease features were tested as predictors of maternal flares and APOs. RESULTS: The study included 238 women (98.3% on hydroxychloroquine (HCQ)) with 230 live births. Thirty-five (14.7%) patients had at least one flare during the second/third trimester. At least one APOs occurred in 34 (14.3%) women. Hypocomplementemia in the first trimester was the only factor associated with maternal flares later in pregnancy (P=0.02), while several factors were associated with APOs. In the logistic regression models, damage by SLICC-Damage Index [odds ratio (OR) 1.8, 95% CI: 1.1, 2.9 for model 1 and OR 1.7, 95% CI: 1.1, 2.8 for model 2] and lupus anticoagulant (LA, OR 4.2, 95% CI: 1.8, 9.7 for model 1; OR 3.7, 95% CI: 1.6, 8.7 for model 2) were significantly associated with APOs. CONCLUSION: LA and damage at conception were predictors of APOs, and hypocomplementemia in the first trimester was associated with maternal flares later in pregnancy in this cohort of pregnant patients mostly with well-controlled SLE treated with HCQ. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02450396.
引用
- Larosa M, Le Guern V, Guettrot-Imbert G, et al. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study. Rheumatology (Oxford). 2022. PMID: 35015828. doi:10.1093/rheumatology/keab943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。